Apyx Medical Corp
For the period ended Jun 30, 2024. Filed Aug 8, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2024 · Filed Aug 8, 2024
APYX$2.94+0.3%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets at
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)
| June 30, 2024(Unaudited) | December 31, 2023 | |
|---|---|---|
| ASSETS | ||
| Current assets: | ||
| Cash and cash equivalents | $32,678 | $43,652 |
| Trade accounts receivable, net of allowance of $650 and $608 | 12,709 | 14,023 |
| Inventories, net of provision for obsolescence of $916 and $875 | 9,324 | 9,923 |
| Prepaid expenses and other current assets | 1,960 | 2,764 |
| Total current assets | 56,671 | 70,362 |
| Property and equipment, net of accumulated depreciation and amortization of $3,783 and $3,522 | 1,918 | 1,915 |
| Operating lease right-of-use assets | 4,935 | 5,162 |
| Finance lease right-of-use assets | 59 | 69 |
| Other assets | 1,811 | 1,732 |
| Total assets | $65,394 | $79,240 |
| LIABILITIES AND EQUITY | ||
| Current liabilities: | ||
| Accounts payable | $2,348 | $2,712 |
| Accrued expenses and other current liabilities | 7,958 | 9,661 |
| Current portion of operating lease liabilities | 313 | 347 |
| Current portion of finance lease liabilities | 20 | 20 |
| Total current liabilities | 10,639 | 12,740 |
| Long-term debt, net of debt discounts and issuance costs | 33,628 | 33,185 |
| Long-term operating lease liabilities | 4,697 | 4,896 |
| Long-term finance lease liabilities | 43 | 53 |
| Long-term contract liabilities | 1,271 | 1,246 |
| Other liabilities | 192 | 198 |
| Total liabilities | 50,470 | 52,318 |
| EQUITY | ||
| Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 issued and outstanding as of June 30, 2024 and December 31, 2023 | — | — |
| Common stock, $0.001 par value; 75,000,000 shares authorized; 34,643,926 issued and outstanding as of June 30, 2024, and 34,643,888 issued and outstanding as of December 31, 2023 | 35 | 35 |
| Additional paid-in capital | 83,292 | 81,114 |
| Accumulated deficit | (68,580) | (54,448) |
| Total stockholders’ equity | 14,747 | 26,701 |
| Non-controlling interest | 177 | 221 |
| Total equity | 14,924 | 26,922 |
| Total liabilities and equity | $65,394 | $79,240 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.